Pfizer Prices Covid Drug Paxlovid At $1,400 For A Five-Day Course; Drugmaker Is Expected To Offer Steep Discounts To Ensure Wide Access
Portfolio Pulse from Benzinga Newsdesk
Pfizer has announced that it will price its Covid-19 drug Paxlovid at nearly $1,400 for a five-day course, more than double what the U.S. government has paid. The drugmaker is expected to offer steep discounts to ensure wide access when commercial sales begin later this year.
October 18, 2023 | 8:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BioNTech, Pfizer's partner in Covid-19 vaccine development, is not directly mentioned in the news about Paxlovid's pricing. Therefore, the impact on its stock is likely to be minimal.
BioNTech, although a partner of Pfizer in the development of a Covid-19 vaccine, is not directly involved in the Paxlovid drug. Therefore, the news about Paxlovid's pricing is unlikely to have a significant impact on BioNTech's stock.
CONFIDENCE 90
IMPORTANCE 20
RELEVANCE 20
NEUTRAL IMPACT
Pfizer's decision to price its Covid-19 drug Paxlovid at $1,400 could potentially increase its revenues, but the expected discounts might offset this. The news could have a mixed impact on the stock.
The pricing of Paxlovid at $1,400 is significantly higher than what the U.S. government has paid, which could increase Pfizer's revenues. However, the company is expected to offer discounts to ensure wide access, which might offset the potential revenue increase. This could lead to a mixed impact on Pfizer's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100